Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus Story 3 Healthcare Stocks Using AI to Drive GrowthWritten by Chris Markoch. Published 9/27/2025. 
Key Points - Discover how three healthcare companies use AI to improve patient outcomes and reduce physician burnout.
- Learn why Hims & Hers, Tempus AI, and Boston Scientific are positioned for growth as AI adoption accelerates.
- See how AI is transforming telehealth, precision medicine, and medical devices to drive efficiency in healthcare.
Artificial intelligence (AI) is transforming the world much like the internet did three decades ago. Beyond its applications in search, AI is revolutionizing how industries manage administrative tasks, with healthcare among the most affected. Generative and agentic AI are helping physicians and care teams deliver more accurate diagnoses, streamline administrative workflows, and reduce provider burnout. According to Athenahealth’s third Physician Sentiment Survey (PSS), 93% of physicians feel burned out regularly. Warren Buffett is the greatest value investor of all time. But even the Oracle of Omaha has limits.
Because of Berkshire Hathaway's size, Buffett simply can't invest in small-cap stocks without taking controlling stakes. That means some of the market's most promising companies are completely off his radar.
But they don't have to be off yours.
We've put together a brand-new report profiling 5 small-cap stocks that check all the boxes of Buffett's investing criteria solid financials, durable business models, strong management, and clear growth catalysts.
The only difference?
These stocks are flying under Wall Street's radar and still accessible to individual investors like you. >> Click here to get your free copy of this report As the population ages, existing supply and demand imbalances in healthcare will intensify. AI technologies offer a way to bridge the gap between operational efficiency and personalized patient care. That makes companies already deploying AI to enhance outcomes and efficiency attractive to investors. Here are three healthcare stocks poised to benefit from these trends and positioned for future growth. AI-Enhanced Telehealth at Scale Hims & Hers Health Inc. (NYSE: HIMS) has been one of the best-performing stocks of 2025, up 121% year-to-date and 29% over the 30 days ending September 24. While some of those gains reflect attention from the meme stock crowd, the company’s growth story remains compelling for long-term investors. Built for telehealth, Hims & Hers is integrating AI to eliminate inefficiencies in its platform. The company uses AI-driven triage to sort patient concerns, automates follow-up reminders, and streamlines prescription refills. At $53.86 per share as of this writing, HIMS is down about 21% from its February all-time high and has twice encountered resistance near $65. High trading volumes suggest that traders—including short sellers—are influencing the price action. Nevertheless, long-term investors need not be deterred. Analysts maintain a consensus Hold rating, but on September 12, Canaccord Genuity Group reiterated a Buy rating and set a $68 price target. With AI driving continued efficiency gains, timing your entry could pay off. Precision Medicine and Oncology Insights Tempus AI (NASDAQ: TEM) applies machine learning and AI to genomic, clinical, and molecular data to advance precision medicine and improve patient outcomes. The company’s oncology focus adds another catalyst: its AI tools help physicians tailor cancer treatment plans, predict patient outcomes, and identify real-time clinical trial opportunities. Tempus’s relevance extends beyond physicians’ offices: 19 of the world’s top 20 pharmaceutical companies use Tempus data in drug discovery. In September, the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device, enhancing RNA sequencing capabilities across the industry. Like HIMS, TEM stock has seen volatile trading in 2025, rising 128% year-to-date and 17% over the past three months. Despite over 25% short interest and resistance near its all-time high of $89, analysts remain bullish and are raising their price targets. Smarter Devices with AI Integration Boston Scientific Corp. (NYSE: BSX) is leveraging AI to enhance its medical devices and digital health solutions, improving data processing efficiency and clinical outcomes. These innovations allow clinicians to focus on patient care while AI automates monitoring and diagnostic tasks. A recent catalyst was the FDA approval of its FARAPULSE pulsed-field ablation system for expanded use in treating certain forms of atrial fibrillation, a condition affecting nearly 60 million people. Since the announcement, at least two analysts have reaffirmed Buy ratings on BSX stock and set price targets well above consensus. BSX stock is up about 17% in 2025, aligning more closely with the S&P 500. However, unlike HIMS and TEM, it has struggled to break past its 52-week high.
| 
